ArticleScientific reports2026
Tellurium-118 as a novel radionuclide for long-term positron emission tomography.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Positron emission tomography (PET) is a powerful imaging modality that tracks positron-emitting radionuclides, enabling non-invasive and high-resolution visualization of biological targets and processes. However, conventional PET tracers possess short half-lives, which limits their utility for long-term pharmacokinetic studies of slow-clearing agents such as antibodies. To address this unmet need, we developed and evaluated tellurium-118 (118Te), a long-lived radionuclide (T₁/₂ = 6.0 days) that decays via electron capture to produce antimony-118 (118Sb), a short-lived positron emitter (T₁/₂ = 3.5 min). This decay cascade allows 118Te to function as an in vivo radionuclide generator, providing sustained positron emission from a single administration. We successfully produced 118Te and performed PET imaging with NEMA and Derenzo phantoms, confirming its PET images with sufficient spatial resolution. In vivo PET/CT imaging of mice following intravenous administration of 118Te revealed the persistence of PET signals in the abdominal region up to three weeks post-injection. Ex vivo biodistribution analysis confirmed the prolonged retention of radioactivity in abdominal organs, particularly the liver and spleen. These findings demonstrate the feasibility of 118Te as a long-lived PET radionuclide for extended molecular imaging. Its unique decay profile and sustained signal generation make it a promising candidate for longitudinal pharmacokinetic studies and radiotheranostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.